339 patents currently held
23 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
62 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
137
Ending by 2030
Nov 2026
Next term end
110
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Jul 2030 · Low confidence
Also notable
Ends Aug 2028 · High confidence
Also notable
Ends Oct 2028 · High confidence
Combined Automated Parallel Synthesis of Polynucleotide Variants
US 8,383,346
Cited by 132 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ketoreductase Polypeptides for the Production of (R)-3-Hydroxythiolane
US 7,977,078
Cited by 113 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Ketoreductase Polypeptides for the Production of Azetidinone
US 7,883,879
Cited by 104 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 14 to 21, 2026 · next Nov 14
- 5 fees due Dec 4 to 30, 2026 · next Dec 4
- 3 fees due Jan 18 to 23, 2027 · next Jan 18
- 9 fees due Feb 1 to 22, 2027 · next Feb 1
- 10 fees due Mar 1 to 26, 2027 · next Mar 1
- 7 fees due Apr 1 to 30, 2027 · next Apr 1
- 5 fees due May 3 to 26, 2027 · next May 3
- 4 fees due Jun 3 to 19, 2027 · next Jun 3
- 7 fees due Jul 5 to 28, 2027 · next Jul 5
- 6 fees due Aug 4 to 27, 2027 · next Aug 4
- 8 fees due Sep 12 to 30, 2027 · next Sep 12
- 5 fees due Oct 14 to 28, 2027 · next Oct 14
- 1 fee due Nov 5, 2027The maintenance fee for Engineered Phenylalanine Ammonia Lyase Polypeptides (US 10,640,759) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 4 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 110 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | 16 in force | to Sep 2033 |
| Biocatalysts and Methods for the Synthesis of Armodafinil | 11 in force | to Dec 2031 |
| Transaminase Polypeptides | 11 in force | to Feb 2031 |
| Ketoreductase Polypeptides for the Production of Azetidinone | 11 in force | to Oct 2028 |
| Ketoreductase Polypeptides for the Production of (R)-3-Hydroxythiolane | 10 in force | to Aug 2028 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,629,157 | Ketoreductase Polypeptides and Related Polynucleotides In force · High confidence | In force | High confidence | |
| US 7,879,585 | Ketoreductase Enzymes and Uses Thereof In force · High confidence | In force | High confidence | |
| US 7,824,898 | Halohydrin Dehalogenases and Related Polynucleotides In force · High confidence | In force | High confidence | |
| US 8,980,605 | Ketoreductases and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,719,071 | Ketoreductase Polypeptides for the Production of Azetidinone In force · High confidence | In force | High confidence | |
| US 9,873,863 | Polynucleotides Encoding Ketoreductase Polypeptides for Reduction of Acetophenones In force · High confidence | In force | High confidence | |
| US 9,951,318 | Ketoreductase Polypeptides for the Reduction of Acetophenones In force · High confidence | In force | High confidence | |
| US 10,227,572 | Ketoreductase Polypeptides for the Reduction of Acetophenones In force · High confidence | In force | High confidence | |
| US 10,597,641 | Ketoreductase Polypeptides for the Production of Azetidinone In force · High confidence | In force | High confidence | |
| US 10,927,351 | Ketoreductase Polypeptides for the Reduction of Acetophenones In force · High confidence | In force | High confidence |
Also on record, not counted in the 339: 23 patents in force now held by others · 130 patents ended · 77 applications pending · 135 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.